Clinical trials
Stem Cell clinical trials
Below are recruiting stem cell clinical trials, each written for real people, not researchers. We’re tracking 740 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04774536RecruitingPhase 1/Phase 2
CRISPR gene-edited bone marrow transplant for severe sickle cell
This Phase 1/2 study tests a CRISPR-edited bone marrow (stem cell) transplant to treat severe sickle cell disease. It aims to reduce dangerous sickle-related complications by changing the patient’s stem cells before transplant.
Los Angeles, CaliforniaAges 12–35 - NCT04819841RecruitingPhase 1/Phase 2
Gene correction using your own stem cells to improve sickle disease
This trial tests a gene-correction treatment that changes sickle hemoglobin (HbS) into normal hemoglobin (HbA) using your own stem cells. It may help reduce severe sickle cell complications for people with severe disease who meet specific safety and medical criteria.
Los Angeles, CaliforniaAges 12–50 - NCT06247501RecruitingPhase 2
CAR-T therapy for children with B-cell ALL needing transplant
This study tests a new type of immune-cell therapy (called CAR-T cells) for children and young adults with a specific blood cancer (B-cell ALL) who need a stem cell transplant. The treatment uses a patient's own T-cells that are modified to find and kill cancer cells with the CD19 marker.
SeoulAges Up to 25 years - NCT06798623RecruitingPhase 1
ACL repair with stem cells from your own knee fat
This trial tests whether adding stem cells from your knee fat pad to a standard ACL reconstruction helps you heal better. It is for Houston Methodist patients who can do physical therapy there and meet basic health requirements.
Houston, TexasAges 18 years+ - NCT05190653Recruiting
Support during stem cell or CAR T cancer treatment
This study tests whether starting palliative and supportive care early (alongside cancer treatment) can improve comfort and support for people having stem cell transplant or CAR T-cell therapy. It may also help family caregivers by offering support during a difficult treatment period.
Calgary, AlbertaAges 18 years+ - NCT05711667RecruitingPhase 3
Letermovir to prevent CMV after stem cell transplant in kids
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Birmingham, AlabamaAges 2–18 - NCT00801333Recruiting
Create patient-specific stem cells for research
This study uses adult body cells (from participants) to create special lab cells called stem cells for research. It’s mainly about whether cells can be made and studied, not about treating a disease.
JerusalemAges 18 years+ - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06581081Recruiting
CAR-T therapy with or without stem cell transplant for B-cell leukemia
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Beijing, Beijing MunicipalityAges 12–65 - NCT04832607RecruitingPhase 3
Donor T-cell treatment for stubborn CMV, EBV, or Adenovirus after transplant
This Phase 3 trial tests giving special immune cells from your stem-cell donor to treat difficult-to-control viral infections after a stem cell transplant. It may help your body fight the virus when standard antiviral medicines haven’t worked well enough.
BrusselsAges 2 months+ - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT02859402RecruitingPhase 2
Donor stem cell transplant for relapsed T or NK lymphoma
This Phase 2 study tests an allogeneic (donor) stem cell transplant for people with T-cell or NK-cell lymphomas that came back or did not respond to prior treatment. It may help by giving you new, healthy immune cells that can attack the cancer.
BusanAges 19–65 - NCT07777406Recruiting
Real-world study of donor stem cell transplant for relapsed/refractory myeloma
This study looks at real-world outcomes in patients who have had a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to gather info on how well this approach works in everyday practice.
Chieti, CHAges 18 years+ - NCT06792682RecruitingPhase 1
Cord blood cells for poor graft function after transplant
This study tests whether umbilical cord blood cells can help patients whose blood counts have dropped again after a stem cell transplant. It may be an option for people who have recovered initially but later develop low blood cell levels.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT03921047Recruiting
Study of T cells during stem cell transplant for AML
This study looks at changes in your immune cells (T cells) in people with acute myeloid leukemia (AML) who are scheduled for a donor stem cell transplant. It may help doctors better understand how the immune system responds during and after transplant.
Los Angeles, CaliforniaAges 18 years+ - NCT05561387RecruitingPhase 3
Drug combinations for newly diagnosed myeloma without transplant
This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.
Anchorage, AlaskaAges Any age - NCT07105579RecruitingPhase 2
Blinatumomab and donor cells after transplant for high-risk B-ALL
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
HangzhouAges 14–65 - NCT06297551Recruiting
Study of leukemia stem cell markers in AML
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
Stony Brook, New YorkAges 18 years+ - NCT06708507Recruiting
Immune cells in graft-versus-host disease
This study looks at special immune cells in the body that may be involved in graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to better understand these cells to improve future treatments for GVHD.
Guangzhou, Other (Non U.s.)Ages 18–65 - NCT07471074Recruiting
Study of stem cells in Waldenström macroglobulinemia
This study looks at bone marrow stem cells in people with Waldenström macroglobulinemia (WM). It aims to understand how these cells work and may help improve future treatments for WM.
AmiensAges 18 years+ - NCT04014374Recruiting
Safety study for stem cell transplant after mogamulizumab
This study tracks safety in adults who had a stem cell transplant after taking mogamulizumab. It looks at outcomes and side effects over time, helping doctors understand risks for future patients.
Milwaukee, WisconsinAges 18 years+ - NCT06689800Recruiting
Family communication tool for kids getting transplant or cell therapy
This study looks at a family communication tool for children and teens getting stem cell transplants or cellular therapy. It helps families talk about treatment together.
St Louis, MissouriAges 8 years+ - NCT07191847RecruitingPhase 4
Stem cell eye drops for dry eye disease
This trial tests whether stem cell fortified eye drops can improve tear film stability, tear volume, and dry eye symptoms. If you have dry eye disease and haven't had eye surgery or certain other eye conditions, you may be able to join.
GizaAges 18–80 - NCT02445534Recruiting
Registry for cell therapy in non-ischemic dilated heart muscle disease
This is a research registry that follows people with non-ischemic dilated cardiomyopathy (a weakened heart muscle) who are already on the right medications. It helps doctors better understand how cell-based therapy and related care affect heart function over time.
LjubljanaAges 18–65
Hear when a new Stem Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for stem cell?
- Yes. Clin2 currently lists 740 recruiting stem cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a stem cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a stem cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.